Opinion/decision on a Paediatric investigation plan (PIP): aluminium hydroxide adsorbed,depigmented glutaraldehyde polymerised,alder pollen,birch pollen,hazel pollen, decision type: , therapeutic area: , PIP number: P/0548/2022

Opinion/decision on a Paediatric investigation plan (PIP): Mayzent,Siponimod (hemifumarate), decision type: , therapeutic area: , PIP number: P/0531/2022

Opinion/decision on a Paediatric investigation plan (PIP): aluminium hydroxide adsorbed,depigmented glutaraldehyde polymerised,birch pollen, decision type: , therapeutic area: , PIP number: P/0527/2022

Opinion/decision on a Paediatric investigation plan (PIP): aluminium hydroxide adsorbed,depigmented glutaraldehyde polymerised,birch pollen,alder pollen,hazel pollen, decision type: , therapeutic area: , PIP number: P/0526/2022

Human medicines European public assessment report (EPAR): Pedmarqsi, sodium thiosulfate, Ear Diseases;Ototoxicity, Date of authorisation: 26/05/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Blenrep, belantamab mafodotin, Multiple Myeloma, Date of authorisation: 25/08/2020, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Norvir, ritonavir, HIV Infections, Date of authorisation: 25/08/1996, Revision: 69, Status: Authorised

Herbal medicinal product: Ginseng radix, Ginseng radix, F: Assessment finalised

Management Board meeting: 5 October 2023, European Medicines Agency, Amsterdam, the Netherlands, from 05/10/2023 to 05/10/2023

Minutes – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG)